United Therapeutics CEO exercises, sells 9,500 shares
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt reported an exercise-and-sell transaction in company stock.
Rhea-AI Filing Summary
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt reported an exercise-and-sell transaction in company stock. On May 29, 2026, she exercised 9,500 stock options at an exercise price of $146.03 per share and sold 9,500 shares of common stock in multiple open‑market trades at weighted average prices in the mid‑$550s, all pursuant to a pre‑arranged 10b5‑1 trading plan. Following these transactions, she directly holds 40,513 shares of common stock and 135,910 stock options, in addition to indirect holdings through family trusts and her spouse.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 9,500 shares ($3.87M approx. pre-tax spread)
Exercise and Sale
19 txns
Insider
ROTHBLATT MARTINE A
Role
Chairperson & CEO
Sold
9,500 shs ($5.26M)
Approx. gross sale proceeds
$5.26M
Approx. exercise cost
$1.39M
Approx. pre-tax spread
$3.87M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option | 9,500 | $0.00 | $0.00 |
| Exercise | Common Stock | 9,500 | $146.03 | $1.39M |
| Sale | Common Stock | 280 | $548.6021 | $154K |
| Sale | Common Stock | 769 | $549.5933 | $423K |
| Sale | Common Stock | 1,605 | $550.5963 | $884K |
| Sale | Common Stock | 986 | $551.3392 | $544K |
| Sale | Common Stock | 680 | $552.5793 | $376K |
| Sale | Common Stock | 823 | $553.7262 | $456K |
| Sale | Common Stock | 817 | $554.5662 | $453K |
| Sale | Common Stock | 1,000 | $555.5876 | $556K |
| Sale | Common Stock | 461 | $556.6691 | $257K |
| Sale | Common Stock | 918 | $557.7969 | $512K |
| Sale | Common Stock | 841 | $558.811 | $470K |
| Sale | Common Stock | 320 | $559.41 | $179K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option — 135,910 contracts (Direct);
Common Stock — 40,513 shares (Direct);
Common Stock — 166 shares (Indirect, by Spouse);
Common Stock — 628,049 shares (Indirect, by Trust)
Footnotes (17)
- F1. This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026.
- F10. This transaction was executed in multiple trades at prices ranging from $556.24 to $557.13. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F11. This transaction was executed in multiple trades at prices ranging from $557.25 to $558.20. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F12. This transaction was executed in multiple trades at prices ranging from $558.37 to $559.23. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F13. This transaction was executed in multiple trades at prices ranging from $559.38 to $559.44. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F14. Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
- F15. Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
- F16. Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
- F17. Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
- F2. This transaction was executed in multiple trades at prices ranging from $548.04 to $548.85. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3. This transaction was executed in multiple trades at prices ranging from $549.06 to $549.94. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4. This transaction was executed in multiple trades at prices ranging from $550.06 to $551.05. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5. This transaction was executed in multiple trades at prices ranging from $551.06 to $551.91. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F6. This transaction was executed in multiple trades at prices ranging from $552.07 to $552.91. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F7. This transaction was executed in multiple trades at prices ranging from $553.09 to $554.08. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F8. This transaction was executed in multiple trades at prices ranging from $554.09 to $555.07. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F9. This transaction was executed in multiple trades at prices ranging from $555.10 to $556.08. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Key Figures
Options exercised: 9,500 shares
Option exercise price: $146.03 per share
Shares sold: 9,500 shares
+5 more
8 metrics
Options exercised
9,500 shares
Stock options exercised into common stock on May 29, 2026
Option exercise price
<money>$146.03</money> per share
Exercise price for 9,500 stock options
Shares sold
9,500 shares
Total common shares sold in open‑market trades on May 29, 2026
Sale price range
<money>$548.04</money>–<money>$559.44</money> per share
Price ranges cited in multiple weighted‑average sale footnotes
Direct common shares after
50,013 shares
Direct United Therapeutics common stock held after transactions
Options outstanding after
135,910 options
Stock options remaining directly held after the exercise
Planned option exercises
1,734,410 options
Maximum options referenced in 10b5‑1 plan, expiring March 17, 2027
Plan end date
<date>December 31, 2026</date>
Latest date the 10b5‑1 trading plan will remain in effect
Key Terms
10b5-1 trading plan, weighted average price, stock options, family trusts, +1 more
5 terms
10b5-1 trading plan financial
"exercise of stock options and sale ... was pursuant to a pre-arranged 10b5-1 trading plan"
A 10b5-1 trading plan is a pre-arranged strategy that allows company insiders to buy or sell company stock at set times, regardless of their current knowledge about the company's situation. It acts like a scheduled appointment for trading, helping prevent the appearance of impropriety or insider trading. This plan provides a way for insiders to sell or buy shares in a controlled, transparent manner, offering reassurance to investors about fair trading practices.
weighted average price financial
"The price reported above reflects the weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
stock options financial
"exercise of stock options and sale of the resulting shares of common stock"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
family trusts financial
"Shares held in family trusts as to which the Reporting Person shares investment power"
exercise or conversion of derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did UTHR CEO Martine Rothblatt report on May 29, 2026?
Martine Rothblatt reported an exercise-and-sell transaction. She exercised 9,500 stock options at an exercise price of $146.03 per share and sold 9,500 United Therapeutics common shares in multiple open‑market trades on May 29, 2026 under a pre‑arranged 10b5‑1 plan.
What stock options did Martine Rothblatt exercise in the latest UTHR Form 4?
Rothblatt exercised 9,500 stock options for United Therapeutics stock. These options had an exercise price of $146.03 per share and convert into common stock. The plan referenced in the footnotes contemplates exercising up to 1,734,410 options expiring on March 17, 2027.
Was the UTHR CEO’s May 29, 2026 stock sale made under a Rule 10b5-1 plan?
Yes. The Form 4 specifies a pre-arranged 10b5-1 trading plan. A footnote states the option exercise and related share sale were executed pursuant to a 10b5‑1 plan adopted on November 7, 2025, which runs until certain option exercises or December 31, 2026.
What ongoing 10b5-1 trading plan does the UTHR Form 4 describe?
The Form 4 describes a structured 10b5-1 plan for option exercises. The plan will continue until the earlier of exercising 1,734,410 stock options, all expiring on March 17, 2027, or December 31, 2026, guiding future option exercises and related share sales.
AI-generated analysis. How Rhea-AI works. Not financial advice.
